Wednesday, August 31, 2016

Roth starts AmpliPhi Biosciences at buy

February 13, 2014 by · Leave a Comment 

Roth Capital Partners has initiated coverage of AmpliPhi Biosciences (OTC:APHB) with a “buy” rating and price target of $1. The stock closed at 59 cents on Wednesday.

buy initiationAmpliPhi is developing a validated approach, phage, to combat bacterial infections through its laser guided “smart bomb” approach to address this unmet medical need.

Phage are naturally occurring viruses that infect and kill bacteria but are benign and non-infective to eukaryotic human cells. They are abundant in the natural environment. Bacteriophage have been used for over a century throughout parts of the world as a treatment for bacterial infections, but have not been widely commercially developed for this purpose in the Western World due to the heavy reliance on antibiotics.

AmpliPhi is developing several bacteriophage therapies and has the platform in place to develop many more, writes analyst Joseph Pantginis.

“We see compelling value in AmpliPhi currently, namely because its products are early stage,” he said. “However, due to extensive historical use, we believe this is an unusually de-risked early-stage company.”

Mr. Pantginis figures the development programs at AmpliPhi could be accelerated due to both the unmet medical need and potentially faster development timelines. “We also believe that as the product candidates move forward the partnering potential is high,” he added.

Print Friendly

Comments are closed.

Email Newsletters with Constant Contact